InMode
Israeli medical device manufacturer specializing in minimally invasive aesthetic and surgical technologies. Listed on Nasdaq with global distribution across 100+ countries.
InMode is an Israeli medical device company that designs, manufactures, and markets minimally invasive aesthetic and surgical technologies. Founded in 2008, InMode went public on NASDAQ in 2019 and has become one of Israel's most successful medical device exits and scaling stories.
Product Portfolio
InMode's core technologies include radiofrequency (RF) and ultrasound-based platforms for: aesthetic treatments (skin tightening, fat reduction, cellulite); surgical applications (hemostasis, tissue ablation); and gynecological procedures. Popular product lines include Morpheus8, BodyTite, and FaceTite—used by dermatologists, plastic surgeons, and aesthetic clinics globally.
Market Position
InMode operates in the minimally invasive aesthetics market, which has exploded alongside social media-driven demand for non-surgical cosmetic procedures. The company competes with Staar Surgical, Cynosure, and others but has differentiated through RF/ultrasound efficacy and brand strength. Market cap has fluctuated but maintains multi-billion-dollar valuations.
Clinical Validation & Regulation
InMode's devices are FDA-cleared (predicate device pathway) and CE-marked for European markets. Clinical validation through peer-reviewed publications and clinical conferences drives adoption and reimbursement. The company funds clinical trials and partnerships with academic medical centers.
Capital Structure & Growth
InMode raised venture capital (early rounds) before IPO. Post-IPO growth has been driven by: direct-to-consumer sales in North America; international expansion in Europe and Asia-Pacific; and strategic acquisitions (Lumenis' aesthetic business). Gross margins are healthy (~70%), supporting R&D and marketing spend.
Israeli Medtech Ecosystem Role
InMode exemplifies the Israeli medical device export model: deep clinical expertise, regulatory know-how, manufacturing capability, and global distribution networks. The company is a flagship employer and exits model for Israeli medtech VCs and angels.